Becton, Dickinson and Co. | BDX - Bruttoergebnis Vom Umsatz

Aktienkurs
144.48
Täglich Wechseln
0.30 0.21%
Monatlich
-7.10%
Jährlich
-16.13%
Q2 Prognose
146.34




Bruttoergebnis Vom Umsatz Veränderung Datum
Abbott USD 5.86B 675M 2026-03
Agilent USD 946M 44M 2025-12
Align Technology USD 736.59M 53M 2026-03
AngioDynamics USD 44.78M 2.93M 2025-09
Avanos Medical USD 94.2M 8.2M 2026-03
Baxter International USD 891M 314M 2026-03
Becton, Dickinson and Co. USD 2.15B 257M 2026-03
Bio-Rad Laboratories USD 345.2M 1.8M 2025-12
Boston Scientific USD 3.61B 64M 2026-03
Cooper Companies USD 695.2M 44.4M 2025-12
Danaher USD 3.59B 375M 2026-03
Dentsply International USD 427M 16M 2026-03
Dexcom USD 750.3M 42.4M 2026-03
Edwards Lifesciences USD 1.29B 59.4M 2026-03
Globus Medical USD 496.26M 39.69M 2026-03
Insulet USD 540.8M 27.8M 2026-03
Integra LifeSciences USD 213.21M 3.89M 2026-03
Intuitive Surgical USD 1.83B 73.8M 2026-03
J&J USD 17.24B 642M 2026-03
Masimo USD 250.8M 3.5M 2026-03
Medtronic USD 5.41B 27M 2025-12
Solventum Corp USD 1.1B 70M 2026-03
Stryker USD 3.81B 675M 2026-03
Tandem Diabetes Care USD 167.46M 33.17M 2025-12
Teleflex USD 307.43M 21K 2026-03
Terumo JPY 153.19B 6.2B 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Zimmer Biomet Holdings USD 1.27B 8.1M 2025-12